It is a Cost Plus Fixed Fee contract for research & development services entitled "Predictive Analytics Point of Care System to Predict Disease Severity Due to Infection."
Prolaris is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness. Scope The contractor shall perform services for the VALBHCS PALMS.
Prolaris is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness. Scope The contractor shall perform services for the VALBHCS PALMS.
and environmental factors that predict population disease patterns for NTM PD.
Findings from this work will have a direct impact on how patients can be molecularly subtyped and for use in assessing target engagement and to predict neurodegenerative disease outcomes.Purpose and Objectives: The purpose of this acquisition is to provide optimization slides, reagents kit, and reagent delivery methods to the laboratories of National Institute on Aging (NIA) at the National Institutes of Health (NIH).
It generates a risk score to help predict the likelihood of disease progression in men with localized prostate cancer. Prolaris is intended to guide the decision regarding active surveillance without surgery or radiation for low- or intermediate-grade cancers vs. active treatment with immediate surgery or radiation therapy.
This work seeks to identify peripheral signatures that could predict the onset of cognitive impairment and Alzheimer’s disease (AD).
